In the top alliance by deal value, Orna Therapeutics (through its ReNAgade Therapeutics subsidiary) entered a three-year research collaboration with Vertex Pharmaceuticals designed to use Orna’s novel lipid nanoparticle delivery vehicles to improve Vertex’s efforts in developing next-generation, gene editing therapies for patients with sickle cell disease and transfusion-dependent Beta thalassemia.
Deals In Depth, January 2025
Ten $1bn+ alliances were penned in January, and two exceeded $2bn.
More from Deal-Making
• By
Laura Lane, European head of Lilly Ventures, talked to In Vivo at the recent Bio-Europe meeting in a fireside chat about how strategic investments are shaping the future of biotech, Lilly's approach to early-stage innovation, and the evolving European investment landscape.
• By
TechBio stands at a critical inflection point, where computational innovation meets the reality of biopharma. Industry leaders have begun to cut through the hype and identify where sustainable value truly lies in this rapidly evolving landscape.
• By
Three $1bn+ alliances were penned in February, and one exceeded $2bn.
• By
An interactive look at pharma, medtech and diagnostics deals made during February 2025. Data courtesy of Biomedtracker.
More from Market Intelligence
• By
Rentschler Biopharma CEO Benedikt von Braunmühl tells In Vivo about the CDMO's strategic decision to exit the cell and gene therapy manufacturing space.
• By
Twenty executives in the biopharma industry outline their expectations for key trends and developments this year. A selection of commentary from a broad industry survey by Scrip.
• By
Swiss firm Molecular Partners and French national offshoot Orano Med have partnered to develop a potent new class of radiopharmaceuticals.